Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Is Mylan Inc. (MYL) Going to Burn These Hedge Funds?

Page 1 of 2

Mylan Inc. (NASDAQ:MYL) was in 27 hedge funds’ portfolio at the end of March. MYL shareholders have witnessed a decrease in enthusiasm from smart money of late. There were 33 hedge funds in our database with MYL holdings at the end of the previous quarter.

To the average investor, there are many metrics shareholders can use to analyze Mr. Market. Some of the most innovative are hedge fund and insider trading activity. At Insider Monkey, our research analyses have shown that, historically, those who follow the best picks of the best investment managers can outperform the broader indices by a significant amount (see just how much).

Mylan Inc. (NASDAQ:MYL)Equally as beneficial, positive insider trading activity is another way to break down the financial markets. There are lots of reasons for a bullish insider to get rid of shares of his or her company, but only one, very clear reason why they would buy. Several academic studies have demonstrated the useful potential of this tactic if investors understand what to do (learn more here).

Consequently, we’re going to take a gander at the latest action surrounding Mylan Inc. (NASDAQ:MYL).

Hedge fund activity in Mylan Inc. (NASDAQ:MYL)

In preparation for this quarter, a total of 27 of the hedge funds we track were bullish in this stock, a change of -18% from one quarter earlier. With hedgies’ capital changing hands, there exists a few noteworthy hedge fund managers who were upping their holdings significantly.

According to our comprehensive database, Paulson & Co, managed by John Paulson, holds the most valuable position in Mylan Inc. (NASDAQ:MYL). Paulson & Co has a $523 million position in the stock, comprising 3% of its 13F portfolio. Coming in second is Jerome Pfund and Michael Sjostrom of Sectoral Asset Management, with a $141 million position; 4.3% of its 13F portfolio is allocated to the company. Other hedgies that hold long positions include Samuel Isaly’s OrbiMed Advisors, Jim Simons’s Renaissance Technologies and Martin D. Sass’s MD Sass.

Seeing as Mylan Inc. (NASDAQ:MYL) has experienced falling interest from the entirety of the hedge funds we track, it’s safe to say that there were a few hedgies that decided to sell off their full holdings last quarter. It’s worth mentioning that D. E. Shaw’s D E Shaw dumped the biggest position of the 450+ funds we monitor, totaling about $143.3 million in stock.. John Kleinheinz’s fund, Kleinheinz Capital Partners, also cut its stock, about $19.5 million worth. These transactions are interesting, as total hedge fund interest dropped by 6 funds last quarter.

How are insiders trading Mylan Inc. (NASDAQ:MYL)?

Insider buying is most useful when the company in focus has seen transactions within the past half-year. Over the last 180-day time period, Mylan Inc. (NASDAQ:MYL) has experienced zero unique insiders buying, and 7 insider sales (see the details of insider trades here).

Let’s also review hedge fund and insider activity in other stocks similar to Mylan Inc. (NASDAQ:MYL). These stocks are Ligand Pharmaceuticals Inc. (NASDAQ:LGND), Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), Akorn, Inc. (NASDAQ:AKRX), Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP), and Actavis Inc (NYSE:ACT). This group of stocks belong to the drugs – generic industry and their market caps are closest to MYL’s market cap.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!